Expertise in
29
conditions

Dr. Luke J. Mountjoy

Oncology
Colorado Blood Cancer Institute
1721 E 19th Ave Ste 100, 
Denver, CO 
Accepting New Patients
Offers Telehealth
Expertise in
29
conditions
Colorado Blood Cancer Institute
1721 E 19th Ave Ste 100, 
Denver, CO 

Overview

Luke Mountjoy is an Oncologist practicing medicine in Denver, Colorado.

Dr. Mountjoy is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 3 clinical trials. Dr. Mountjoy is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IA

Hospital Affiliations

Poudre Valley Hospital
HCA HealthOne Presbyterian St. Lukes

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Colorado Blood Cancer Institute
1721 E 19th Ave Ste 100, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
View 2 Less Clinical Trials

23 Total Publications

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.
Journal: Transplantation and cellular therapy
Published: April 21, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Colorado Blood Cancer Institute

1721 E 19th Ave Ste 100, 
Denver, CO 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Matous is an Oncologist practicing medicine in Denver, Colorado. Dr. Matous is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Matous is currently accepting new patients.

Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (7.3 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rajeev Vibhakar is a Hematologist and an Oncologist practicing medicine in Aurora, Colorado. Dr. Vibhakar is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Gliomatosis Cerebri. Dr. Vibhakar is currently accepting new patients.

Expertise in
15
conditions
Dr. Nicholas K. Foreman
Hematology | Oncology
Expertise in
15
conditions
Dr. Nicholas K. Foreman
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

1811 Plaza Dr, 
Highlands Ranch, CO 
 (12.2 miles away)
720-478-9840
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nicholas Foreman is a Hematologist and an Oncologist practicing medicine in Highlands Ranch, Colorado. Dr. Foreman is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Ependymoma, Brain Tumor, Ganglioglioma, and Medulloblastoma. Dr. Foreman is currently accepting new patients.

Frequently Asked Questions about Dr. Luke J. Mountjoy

Is Dr. Luke J. Mountjoy a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Luke J. Mountjoy is classified as an Distinguished expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Luke J. Mountjoy specialize in?

While Dr. Luke J. Mountjoy is a Oncology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Luke J. Mountjoy participate in research or clinical trials?

Yes. Dr. Luke J. Mountjoy has published 23 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Luke J. Mountjoy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Luke J. Mountjoy accept my insurance?

Dr. Luke J. Mountjoy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mountjoy's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile